In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more.

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster”…

AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.